Logo image of DARE

DARE BIOSCIENCE INC (DARE) Stock Fundamental Analysis

NASDAQ:DARE - US23666P2002 - Common Stock

2.15 USD
+0.02 (+0.94%)
Last: 9/5/2025, 8:06:51 PM
2.18 USD
+0.03 (+1.4%)
After Hours: 9/5/2025, 8:06:51 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to DARE. DARE was compared to 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of DARE have multiple concerns. DARE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year DARE has reported negative net income.
DARE had a positive operating cash flow in the past year.
In the past 5 years DARE always reported negative net income.
DARE had negative operating cash flow in 4 of the past 5 years.
DARE Yearly Net Income VS EBIT VS OCF VS FCFDARE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -9.00%, DARE is in the better half of the industry, outperforming 67.69% of the companies in the same industry.
Industry RankSector Rank
ROA -9%
ROE N/A
ROIC N/A
ROA(3y)-76.89%
ROA(5y)-132.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DARE Yearly ROA, ROE, ROICDARE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K -4K -6K -8K

1.3 Margins

With an excellent Gross Margin value of 108.60%, DARE belongs to the best of the industry, outperforming 99.49% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for DARE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 108.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DARE Yearly Profit, Operating, Gross MarginsDARE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50K -100K -150K -200K

More info and screens

3

2. Health

2.1 Basic Checks

DARE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DARE has more shares outstanding
Compared to 5 years ago, DARE has less shares outstanding
Compared to 1 year ago, DARE has a worse debt to assets ratio.
DARE Yearly Shares OutstandingDARE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
DARE Yearly Total Debt VS Total AssetsDARE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

DARE has an Altman-Z score of -17.40. This is a bad value and indicates that DARE is not financially healthy and even has some risk of bankruptcy.
DARE has a worse Altman-Z score (-17.40) than 77.44% of its industry peers.
The Debt to FCF ratio of DARE is 1.20, which is an excellent value as it means it would take DARE, only 1.20 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of DARE (1.20) is better than 94.87% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 1.2
Altman-Z -17.4
ROIC/WACCN/A
WACC9.82%
DARE Yearly LT Debt VS Equity VS FCFDARE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 0.56 indicates that DARE may have some problems paying its short term obligations.
The Current ratio of DARE (0.56) is worse than 91.79% of its industry peers.
A Quick Ratio of 0.56 indicates that DARE may have some problems paying its short term obligations.
DARE's Quick ratio of 0.56 is on the low side compared to the rest of the industry. DARE is outperformed by 90.77% of its industry peers.
Industry RankSector Rank
Current Ratio 0.56
Quick Ratio 0.56
DARE Yearly Current Assets VS Current LiabilitesDARE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

3

3. Growth

3.1 Past

DARE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -91.96%.
DARE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -99.65%.
EPS 1Y (TTM)-91.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.61%
Revenue 1Y (TTM)-99.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-195.45%

3.2 Future

Based on estimates for the next years, DARE will show a very strong growth in Earnings Per Share. The EPS will grow by 104.29% on average per year.
DARE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 219.09% yearly.
EPS Next Y-289.37%
EPS Next 2Y-26.31%
EPS Next 3Y65.11%
EPS Next 5Y104.29%
Revenue Next Year419.65%
Revenue Next 2Y254.45%
Revenue Next 3Y267.23%
Revenue Next 5Y219.09%

3.3 Evolution

DARE Yearly Revenue VS EstimatesDARE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
DARE Yearly EPS VS EstimatesDARE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -100 -200 -300 -400 -500

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DARE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DARE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DARE Price Earnings VS Forward Price EarningsDARE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

DARE's Price/Free Cash Flow ratio is rather cheap when compared to the industry. DARE is cheaper than 97.95% of the companies in the same industry.
Industry RankSector Rank
P/FCF 4.82
EV/EBITDA N/A
DARE Per share dataDARE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as DARE's earnings are expected to grow with 65.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.31%
EPS Next 3Y65.11%

More info and screens

0

5. Dividend

5.1 Amount

DARE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DARE BIOSCIENCE INC

NASDAQ:DARE (9/5/2025, 8:06:51 PM)

After market: 2.18 +0.03 (+1.4%)

2.15

+0.02 (+0.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-12 2025-11-12
Inst Owners9.34%
Inst Owner Change8.12%
Ins Owners1.15%
Ins Owner Change0%
Market Cap28.98M
Analysts80
Price Target11.9 (453.49%)
Short Float %1.96%
Short Ratio0.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2%
Min EPS beat(2)-19.49%
Max EPS beat(2)15.48%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-98.2%
Min Revenue beat(2)-104.71%
Max Revenue beat(2)-91.69%
Revenue beat(4)0
Avg Revenue beat(4)-99.03%
Min Revenue beat(4)-104.71%
Max Revenue beat(4)-91.69%
Revenue beat(8)1
Avg Revenue beat(8)-58.63%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.26%
PT rev (3m)-12.5%
EPS NQ rev (1m)-11%
EPS NQ rev (3m)-42.62%
EPS NY rev (1m)-1.15%
EPS NY rev (3m)-6.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-37.11%
Revenue NY rev (1m)0%
Revenue NY rev (3m)551.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 323.82
P/FCF 4.82
P/OCF 4.3
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.15
EYN/A
EPS(NY)-0.83
Fwd EYN/A
FCF(TTM)0.45
FCFY20.75%
OCF(TTM)0.5
OCFY23.24%
SpS0.01
BVpS-0.71
TBVpS-0.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 108.6%
FCFM 6719.11%
ROA(3y)-76.89%
ROA(5y)-132.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 1.2
Debt/EBITDA N/A
Cap/Depr 381.33%
Cap/Sales 807.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.56
Quick Ratio 0.56
Altman-Z -17.4
F-Score3
WACC9.82%
ROIC/WACCN/A
Cap/Depr(3y)1097.89%
Cap/Depr(5y)675.4%
Cap/Sales(3y)1956.65%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-91.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.61%
EPS Next Y-289.37%
EPS Next 2Y-26.31%
EPS Next 3Y65.11%
EPS Next 5Y104.29%
Revenue 1Y (TTM)-99.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-195.45%
Revenue Next Year419.65%
Revenue Next 2Y254.45%
Revenue Next 3Y267.23%
Revenue Next 5Y219.09%
EBIT growth 1Y23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y127.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y130.8%
OCF growth 3YN/A
OCF growth 5YN/A